Last reviewed · How we verify

NCT07243873

Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study

Recruiting now Last updated 24 November 2025
What this trial tests

trial testing PET-CT in Lung Cancer in 10,000 participants. Currently enrolling.

Timeline
1 December 2025
Primary endpoint
1 June 2026
1 December 2026

Quick facts

Lead sponsorShanghai Pulmonary Hospital, Shanghai, China
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment10,000
Start date1 December 2025
Primary completion1 June 2026
Estimated completion1 December 2026
Sites5 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

Adults 18 to 85, any sex, with Lung Cancer or PET-CT. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to synthesise PET data that preserves biological relevance and adds clinical value to the diagnosis and prognosis of lung cancer by establishing anatomical-to-metabolic mapping based on paired diagnostic CT and FDG-PET scans, thereby prospectively validating the clinical utility of the model.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PET-CT

Trials testing the same drug.

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07243873.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing